Community Pharmacists’ Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD
Alzheimer’s disease (AD) impacts millions of individuals worldwide. Since no cure is currently available, acetylcholinesterase inhibitors are symptomatic therapy. This study assessed community pharmacists’ knowledge regarding donepezil adverse effects (AEs) and self-care recommendations for insomnia...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-07-01
|
| Series: | Pharmacy |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2226-4787/5/3/42 |
| _version_ | 1798027036568059904 |
|---|---|
| author | Marketa Marvanova Paul Jacob Henkel |
| author_facet | Marketa Marvanova Paul Jacob Henkel |
| author_sort | Marketa Marvanova |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) impacts millions of individuals worldwide. Since no cure is currently available, acetylcholinesterase inhibitors are symptomatic therapy. This study assessed community pharmacists’ knowledge regarding donepezil adverse effects (AEs) and self-care recommendations for insomnia management for persons with AD treated with rivastigmine. This is a cross-sectional, standardized telephone survey of community pharmacists (n = 862) in three study areas: West Virginia, North Dakota/South Dakota, and Southern Oregon/Northern California. Pharmacists’ degree, sex, and pharmacists’ AD-related knowledge were assessed. In-stock availability of donepezil and rivastigmine formulations was assessed. Analyses were performed using Stata 10.1. Only 31.4% pharmacists were able to name ≥2 donepezil AEs. Only four donepezil AEs were named by at least 13% of pharmacists: nausea (36.1%), dizziness (25.1%), diarrhea (15.0%), and vomiting (13.9%). All other AEs were named by fewer than 7% of respondents. Only 62.9% of pharmacists (n = 542) provided appropriate recommendations: melatonin (40.3%), referral to physician (22.0%), or sleep hygiene (0.6%). Over 12% of pharmacists (n = 107) provided inappropriate recommendations (anticholinergic agent or valerian root) and 21.5% of pharmacists were unable to provide any recommendation. We identified significant gaps in community pharmacists’ knowledge regarding donepezil AEs and non-prescription insomnia recommendation needing significant improvement to ensure high-quality AD-related care. |
| first_indexed | 2024-04-11T18:44:53Z |
| format | Article |
| id | doaj.art-1de2012c905243a9ac70952ccc42bf14 |
| institution | Directory Open Access Journal |
| issn | 2226-4787 |
| language | English |
| last_indexed | 2024-04-11T18:44:53Z |
| publishDate | 2017-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmacy |
| spelling | doaj.art-1de2012c905243a9ac70952ccc42bf142022-12-22T04:08:51ZengMDPI AGPharmacy2226-47872017-07-01534210.3390/pharmacy5030042pharmacy5030042Community Pharmacists’ Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with ADMarketa Marvanova0Paul Jacob Henkel1Department of Pharmacy Practice, School of Pharmacy/College of Health Professions, North Dakota State University, Department 2650, P.O. Box 6050, Fargo, ND 58108-6050, USADepartment of Geographical and Historical Studies, University of Eastern Finland, FI-80101 Joensuu, FinlandAlzheimer’s disease (AD) impacts millions of individuals worldwide. Since no cure is currently available, acetylcholinesterase inhibitors are symptomatic therapy. This study assessed community pharmacists’ knowledge regarding donepezil adverse effects (AEs) and self-care recommendations for insomnia management for persons with AD treated with rivastigmine. This is a cross-sectional, standardized telephone survey of community pharmacists (n = 862) in three study areas: West Virginia, North Dakota/South Dakota, and Southern Oregon/Northern California. Pharmacists’ degree, sex, and pharmacists’ AD-related knowledge were assessed. In-stock availability of donepezil and rivastigmine formulations was assessed. Analyses were performed using Stata 10.1. Only 31.4% pharmacists were able to name ≥2 donepezil AEs. Only four donepezil AEs were named by at least 13% of pharmacists: nausea (36.1%), dizziness (25.1%), diarrhea (15.0%), and vomiting (13.9%). All other AEs were named by fewer than 7% of respondents. Only 62.9% of pharmacists (n = 542) provided appropriate recommendations: melatonin (40.3%), referral to physician (22.0%), or sleep hygiene (0.6%). Over 12% of pharmacists (n = 107) provided inappropriate recommendations (anticholinergic agent or valerian root) and 21.5% of pharmacists were unable to provide any recommendation. We identified significant gaps in community pharmacists’ knowledge regarding donepezil AEs and non-prescription insomnia recommendation needing significant improvement to ensure high-quality AD-related care.https://www.mdpi.com/2226-4787/5/3/42community pharmacistpharmaceutical careAlzheimer’s diseasecognitive enhanceracetylcholinesterase inhibitordonepezilrivastigmineanticholinergic agent |
| spellingShingle | Marketa Marvanova Paul Jacob Henkel Community Pharmacists’ Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD Pharmacy community pharmacist pharmaceutical care Alzheimer’s disease cognitive enhancer acetylcholinesterase inhibitor donepezil rivastigmine anticholinergic agent |
| title | Community Pharmacists’ Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD |
| title_full | Community Pharmacists’ Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD |
| title_fullStr | Community Pharmacists’ Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD |
| title_full_unstemmed | Community Pharmacists’ Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD |
| title_short | Community Pharmacists’ Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD |
| title_sort | community pharmacists knowledge regarding donepezil averse effects and self care recommendations for insomnia for persons with ad |
| topic | community pharmacist pharmaceutical care Alzheimer’s disease cognitive enhancer acetylcholinesterase inhibitor donepezil rivastigmine anticholinergic agent |
| url | https://www.mdpi.com/2226-4787/5/3/42 |
| work_keys_str_mv | AT marketamarvanova communitypharmacistsknowledgeregardingdonepezilaverseeffectsandselfcarerecommendationsforinsomniaforpersonswithad AT pauljacobhenkel communitypharmacistsknowledgeregardingdonepezilaverseeffectsandselfcarerecommendationsforinsomniaforpersonswithad |